308 related articles for article (PubMed ID: 29153870)
1. Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey.
Gaitonde P; Bozzi LM; Shaya FT
Semin Arthritis Rheum; 2018 Apr; 47(5):649-653. PubMed ID: 29153870
[TBL] [Abstract][Full Text] [Related]
2. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
4. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.
Solomon DH; Ayanian JZ; Yelin E; Shaykevich T; Brookhart MA; Katz JN
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):184-9. PubMed ID: 22012868
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
7. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
9. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
Yazdany J; Tonner C; Schmajuk G; Lin GA; Trivedi AN
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1447-55. PubMed ID: 25244314
[TBL] [Abstract][Full Text] [Related]
10. Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.
Gossen N; Jacob L; Kostev K
Rheumatol Int; 2016 Aug; 36(8):1113-8. PubMed ID: 26936261
[TBL] [Abstract][Full Text] [Related]
11. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey.
Solomon DH; Yelin E; Katz JN; Lu B; Shaykevich T; Ayanian JZ
Arthritis Res Ther; 2013 Mar; 15(2):R43. PubMed ID: 23506671
[TBL] [Abstract][Full Text] [Related]
13. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population.
Shipton D; Glazier RH; Guan J; Badley EM
Med Care; 2004 Sep; 42(9):907-13. PubMed ID: 15319617
[TBL] [Abstract][Full Text] [Related]
14. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
15. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Ding Q; Shiltz D; Hossami D; Konieczny AM
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
18. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys.
Ward MM
J Rheumatol; 1999 Mar; 26(3):546-50. PubMed ID: 10090160
[TBL] [Abstract][Full Text] [Related]
19. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
20. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt.
Polinski JM; Brookhart MA; Ayanian JZ; Katz JN; Kim SC; Lii J; Tonner C; Yelin E; Solomon DH
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1634-43. PubMed ID: 24664991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
